Q-omics provides the consensus-scored PRLH profile across patient tissues and cancer cell-line models. PRLH expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRLH is differentially expressed in 8, with the highest sampling consensus in UCEC. Additionally, PRLH protein abundance shows 13,848 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, UCEC, and GBM as cancer lineages where PRLH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRLH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRLH survival associations across molecular data types. PRLH RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRLH RNA expression–survival associations across cancer types. High PRLH expression shows unfavorable associations in KIRC, LUSC, LIHC, READ and THCA, but favorable associations in BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRLH RNA expression.
This table summarizes PRLH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in UCEC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PRLH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRLH shows lower tumor expression in LUAD and LUSC and higher tumor expression in UCEC, BRCA, PAAD and STAD. The UCEC box plot shows higher PRLH RNA expression in tumor versus normal tissue (log2 FC = +0.779, t-test p = .001).
This table shows molecular features associated with PRLH in patient tissues and cancer cell lines. In patient samples, PRLH shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRLH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
